CY1120536T1 - Μεθοδος και συνθεσεις για τη θεραπευτικη αγωγη του καρκινου - Google Patents

Μεθοδος και συνθεσεις για τη θεραπευτικη αγωγη του καρκινου

Info

Publication number
CY1120536T1
CY1120536T1 CY20181100285T CY181100285T CY1120536T1 CY 1120536 T1 CY1120536 T1 CY 1120536T1 CY 20181100285 T CY20181100285 T CY 20181100285T CY 181100285 T CY181100285 T CY 181100285T CY 1120536 T1 CY1120536 T1 CY 1120536T1
Authority
CY
Cyprus
Prior art keywords
compositions
health education
cancer health
cancer
subject
Prior art date
Application number
CY20181100285T
Other languages
Greek (el)
English (en)
Inventor
Angelika Burger
Hans Hendriks
Bernardus Rademaker
Original Assignee
Kominox, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kominox, Inc. filed Critical Kominox, Inc.
Publication of CY1120536T1 publication Critical patent/CY1120536T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/36Arsenic; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20181100285T 2008-03-27 2018-03-09 Μεθοδος και συνθεσεις για τη θεραπευτικη αγωγη του καρκινου CY1120536T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3998708P 2008-03-27 2008-03-27
US12/408,864 US20090246291A1 (en) 2008-03-27 2009-03-23 Method and compositions for treatment of cancer
PCT/US2009/038104 WO2009120697A2 (en) 2008-03-27 2009-03-24 Method and compositions for treatment of cancer

Publications (1)

Publication Number Publication Date
CY1120536T1 true CY1120536T1 (el) 2019-07-10

Family

ID=41114644

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100285T CY1120536T1 (el) 2008-03-27 2018-03-09 Μεθοδος και συνθεσεις για τη θεραπευτικη αγωγη του καρκινου

Country Status (20)

Country Link
US (2) US20090246291A1 (enExample)
EP (1) EP2268292B1 (enExample)
JP (2) JP5543956B2 (enExample)
KR (1) KR101634138B1 (enExample)
CN (2) CN104997808A (enExample)
AU (1) AU2009228378B2 (enExample)
BR (1) BRPI0909164A2 (enExample)
CA (1) CA2719766C (enExample)
CY (1) CY1120536T1 (enExample)
DK (1) DK2268292T3 (enExample)
ES (1) ES2656762T3 (enExample)
HU (1) HUE036609T2 (enExample)
LT (1) LT2268292T (enExample)
MX (1) MX2010010621A (enExample)
PL (1) PL2268292T3 (enExample)
PT (1) PT2268292T (enExample)
RU (1) RU2508116C2 (enExample)
SI (1) SI2268292T1 (enExample)
WO (1) WO2009120697A2 (enExample)
ZA (1) ZA201006988B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
AU2010292192B2 (en) * 2009-09-10 2015-04-02 Kominox, Inc. Cancer stem cell-targeted and drug resistant cancer therapy
US8795738B2 (en) * 2009-11-12 2014-08-05 Board Of Regents Of The University Of Texas System Use of arsenic for cancer therapy protection
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
CN103153303A (zh) * 2010-07-18 2013-06-12 尼基制药公司 使用钌络合物的联合疗法
RU2762111C1 (ru) * 2010-08-24 2021-12-15 Юниверсити Оф Теннесси Рисерч Фаундейшн Соединения для лечения рака
US20120251628A1 (en) * 2011-03-30 2012-10-04 Young Joo Min Compositions and methods for treatment of cancer
US8834938B2 (en) 2011-05-18 2014-09-16 Board Of Regents Of The University Of Texas System Use of arsenic for cancer therapy protection
WO2012155061A1 (en) * 2011-05-12 2012-11-15 Board Of Regents, University Of Texas System Use of arsenic for cancer therapy protection
US20160184356A1 (en) * 2013-03-15 2016-06-30 Ke Jian Jim Liu Arsenic-based treatment of cancers and inflammatory disorders
KR101309844B1 (ko) 2013-03-15 2013-09-23 박상채 항암 활성 증진용 한약재 및 이의 제조방법
JP6851826B2 (ja) * 2013-07-19 2021-03-31 オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. がんの治療のためのpimキナーゼ阻害剤と組み合わせたペプチドエポキシケトンプロテアソーム阻害剤
IL265986B (en) * 2016-12-01 2022-09-01 Eupharma Pty Ltd Pharmaceutical composition comprising an alkali metal and/or an alkaline earth metal diarsenic (iii) tetraoxide and uses thereof
BR112020019425A2 (pt) 2018-03-22 2020-12-29 Komipharm International Australia Pty Ltd Composição farmacêutica compreendendo meta-arsenito e método de fabricação
CN116236505A (zh) * 2023-03-15 2023-06-09 上海市第四人民医院 三氧化二砷在制备肺神经内分泌癌治疗药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875451B2 (en) * 1997-10-15 2005-04-05 Polarx Biopharmaceuticals Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
ES2395515T3 (es) * 1997-11-10 2013-02-13 Memorial Sloan Kettering Cancer Center Trióxido de arsénico para uso en el tratamiento de la leucemia
KR20020083678A (ko) * 2001-04-28 2002-11-04 주식회사 한국미생물연구소 아르세닉산나트륨 염, 소디움 메타아르세나이트 또는 이의혼합물을 함유한 항암제 조성물
DK2042182T3 (da) * 2002-04-10 2013-08-26 Komipharm Int Co Ltd Farmaceutisk sammensætning, der omfatter arsen, til behandling af malignitet.
EP1721615A1 (en) * 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US8097237B2 (en) * 2005-08-23 2012-01-17 Stc.Unm Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma
WO2009049258A1 (en) * 2007-10-12 2009-04-16 The Johns Hopkins University Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies

Also Published As

Publication number Publication date
KR101634138B1 (ko) 2016-06-28
US20090246291A1 (en) 2009-10-01
RU2010143893A (ru) 2012-05-10
ES2656762T3 (es) 2018-02-28
WO2009120697A3 (en) 2010-02-18
LT2268292T (lt) 2018-03-26
MX2010010621A (es) 2011-04-05
EP2268292B1 (en) 2017-12-27
CN104997808A (zh) 2015-10-28
AU2009228378A1 (en) 2009-10-01
CN102046187A (zh) 2011-05-04
JP5543956B2 (ja) 2014-07-09
SI2268292T1 (en) 2018-03-30
AU2009228378B2 (en) 2014-07-17
RU2508116C2 (ru) 2014-02-27
JP2011515481A (ja) 2011-05-19
JP2014101387A (ja) 2014-06-05
KR20110009664A (ko) 2011-01-28
BRPI0909164A2 (pt) 2016-06-21
HUE036609T2 (hu) 2018-07-30
US20180055812A1 (en) 2018-03-01
ZA201006988B (en) 2012-05-30
EP2268292A4 (en) 2011-05-11
PL2268292T3 (pl) 2018-06-29
WO2009120697A2 (en) 2009-10-01
DK2268292T3 (en) 2018-03-12
EP2268292A2 (en) 2011-01-05
PT2268292T (pt) 2018-02-19
CA2719766C (en) 2017-10-31
CA2719766A1 (en) 2009-10-01
WO2009120697A4 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
CY1120536T1 (el) Μεθοδος και συνθεσεις για τη θεραπευτικη αγωγη του καρκινου
CY1120547T1 (el) Νανοσωματιδιο που περιλαμβανει ραπαμυκινη και αλβουμινη ως αντικαρκινικος παραγοντας
CY1118216T1 (el) Μεθοδοι αγωγης καρκινου
CY1125077T1 (el) Αγωγη της ανεπαρκειας και ελλειψης βιταμινης d με 25-υδροξυβιταμινη d2 και 25-υδροξυβιταμινη d3
CY1116264T1 (el) Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2
CL2019000221A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
NZ752526A (en) Pyrrolobenzodiazepine conjugates
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
CY1120102T1 (el) Συνθεσεις και μεθοδοι για μειωση τριγλυκεριδιων χωρις αυξηση επιπεδων ldl-c σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CY1117869T1 (el) Φαρμακοτεχνικες μορφες για απο του στοματος απελευθερωση προσροφητικων στο εντερο
MX2016001236A (es) Anticuerpos anti-fgfr2iiib afucosilados.
MX2015011752A (es) Metodos para tratar cancer de pulmon.
UA107783C2 (en) Isoindoline compounds for use in treating cancer
CY1123490T1 (el) Συνθεσεις που προερχονται απο χιτοζανη
EA201300242A1 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
MX381017B (es) Compuestos peptidomiméticos y conjugados anticuerpo-fármaco de estos.
UY36075A (es) Derivados de tubulisina
CY1124529T1 (el) Ενωσεις λευκοχρυσου λειτουργικοποιημενες με μονομηλεινιμιδιο για θεραπεια καρκινου
CY1118081T1 (el) Παρασκευασματα συνδυασμου με εξωσωματα και κορτικοστεροειδες
CY1122968T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο
EA201690085A1 (ru) Полимерные наночастицы доцетаксела для лечения рака
CY1122998T1 (el) Μεθοδοι και συνθεσεις για την αντιμετωπιση της καταθλιψης χρησιμοποιωντας κυκλοβενζαπρινη
CY1122835T1 (el) Συνδυαστικη θεραπεια
CY1116216T1 (el) Μεθοδος θεραπειας ασθενειας αποθηκευσης γλυκογονου
CY1118254T1 (el) Αντισωματα toy βμρ-6